Greenwich LifeSciences Inc. (GLSI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Greenwich LifeSciences The Overlooked Need
Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer.
Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim
Greenwich LifeSciences (GLSI) remains a "Buy" as phase 3 FLAMINGO-01 advances in HER2-positive breast cancer with two major program updates. Open-label data from FLAMINGO-01 showed an 80% recurrence reduction in non-HLA-A*02 patients, supporting expanded protocol and potential market doubling. Company filed new patent claims based on statistically significant immune response and recurrence open-label data, potentially extending protection through 2045 if upheld.
Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100
Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b study indicated that patients, given GLSI-100 for HER2/neu positive breast cancer, were able to achieve a 100% recurrence free rate. The global breast cancer market size is expected to be worth $49.2 billion by 2032.
Greenwich LifeSciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Joseph Castro Nuveen LLC | 88,717 | $2.13M | $1.71M | -$417,723.65 | -19.6% |
| RS Richard Slavik Newbridge Financial Services Group Inc. | 2,100 | $21,855 | $40,929 | $19,074 | 87.28% |
| OFA Olalekan F. Adeduji Washington Trust Advisors Inc. | 200 | $2,104 | $3,979 | $1,875 | 89.12% |
 Alexandra Stickelman Root Financial Partners, LLC | 5 | $120 | $96.25 | -$23.75 | -19.79% |
 Christopher C. Powers Farther Finance Advisors, LLC | 1,319 | $28,491.93 | $21,526.08 | -$6,965.85 | -24.45% |
Greenwich LifeSciences Inc. (GLSI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Greenwich LifeSciences Inc. ever had a stock split?
Greenwich LifeSciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Snehal S. Patel CEO | NASDAQ (CM) Exchange | 396879108 CUSIP |
| US Country | 13 Employees | - Last Dividend | - Last Split | 25 Sep 2020 IPO Date |
Overview
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of novel cancer immunotherapies targeting breast cancer and other cancers expressing the HER2/neu protein. The company embarked on its journey in the healthcare sector in 2006, initially operating under the name Norwell, Inc. before rebranding to Greenwich LifeSciences, Inc. in March 2018. With its headquarters situated in Stafford, Texas, Greenwich LifeSciences has dedicated itself to the advancement of cancer treatment options through immunotherapeutic approaches, aiming to significantly improve patient outcomes in the fight against cancer.
Products and Services
- GP2 Immunotherapy
At the core of Greenwich LifeSciences’ product pipeline is GP2, an innovative immunotherapy treatment designed to prevent the recurrence of breast cancer in patients who have previously undergone surgery. Currently in Phase III clinical trials, GP2 represents a breakthrough in cancer care, offering hope for durable remission by harnessing the body's immune system to fight off cancer cells. The focus on HER2/neu-expressing cancers positions GP2 as a crucial development in the realm of oncology, potentially setting new standards for cancer immunotherapy treatments.
